Virios Therapeutics regains Nasdaq minimum bid price compliance

Dogwood Therapeutics, Inc.

Received Nasdaq letter on May 24, 2023 confirming compliance with Listing Rule 5550(a)(2).
Closing bid price was at least $1.00 for ten consecutive business days (May 10–May 23, 2023).
Closes the deficiency notice initially received on November 1, 2022 regarding bid price non-compliance.

item 8.01 item 9.01

Dogwood Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-010423

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.